Korro Bio (NASDAQ:KRRO) Posts Earnings Results, Beats Estimates By $0.15 EPS

Korro Bio (NASDAQ:KRRO) posted its quarterly earnings results on Tuesday. The company reported ($2.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.41) by $0.15, Zacks reports.

Korro Bio Stock Performance

Korro Bio stock opened at $25.06 on Tuesday. Korro Bio has a 1-year low of $18.50 and a 1-year high of $98.00. The firm’s fifty day simple moving average is $30.99 and its 200-day simple moving average is $41.99.

Analysts Set New Price Targets

Several research firms have weighed in on KRRO. HC Wainwright reiterated a “buy” rating and issued a $115.00 price objective on shares of Korro Bio in a research note on Friday, November 22nd. Oppenheimer assumed coverage on shares of Korro Bio in a research note on Friday, January 10th. They issued an “outperform” rating and a $155.00 price target on the stock. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Korro Bio currently has an average rating of “Buy” and an average price target of $144.00.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).